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ABSTRACT
Background: Cystic fibrosis (CF) lung infection is a complex condition where opportunistic
pathogens and defective immune system cooperate in developing a constant cycle of infection
and inflammation. The major pathogen, Pseudomonas aeruginosa, secretes a multitude of viru-
lence factors involved in host immune response and lung tissue damage. In this study, we
examined the possible anti-inflammatory effects of molecules inhibiting P. aeruginosa virulence
factors.
Methods: Pyocyanin, pyoverdine and proteases were measured in bacterial culture supernatant
from different P. aeruginosa strains. Inhibition of virulence factors by sub-inhibitory concentrations
of clarithromycin and by protease inhibitors was evaluated. Lung inflammatory response was
monitored by in vivo bioluminescence imaging in wild-type and CFTR-knockout mice expressing a
luciferase gene under the control of a bovine IL-8 promoter.
Results: The amount of proteases, pyocyanin and pyoverdine secreted by P. aeruginosa strains
was reduced after growth in the presence of a sub-inhibitory dose of clarithromycin. Intratracheal
challenge with culture supernatant containing bacteria-released products induced a strong IL-8-
mediated response in mouse lungs while lack of virulence factors corresponded to a reduction in
bioluminescence emission. Particularly, sole inactivation of proteases by inhibitors Ilomastat and
Marimastat also resulted in decreased lung inflammation.
Conclusions: Our data support the assumption that virulence factors are involved in P. aeruginosa
pro-inflammatory action in CF lungs; particularly, proteases seem to play an important role.
Inhibition of virulence factors production and activity resulted in decreased lung inflammation;
thus, clarithromycin and protease inhibitors potentially represent additional therapeutic therapies
for P. aeruginosa-infected patients.
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Introduction
Cystic fibrosis (CF) lung infection is a complex condi-
tion where opportunistic pathogens and defective
immune system cooperate in developing a constant
cycle of infection and inflammation [1]. Pseudomonas
aeruginosa causes chronic respiratory infections in
more than 50% of adult CF patients, therefore it is
considered the main respiratory pathogen [2]. A period
of initial intermittent, recurrent lung colonization is
described, when antibiotic treatment can temporarily
eradicate the infection. This phase can last for years but
often transition into a chronic infection occurs, indu-
cing a state of chronic inflammation [3]. Indeed,
increased number of neutrophils, alveolar macrophages
and T lymphocytes were found in alveoli of explanted
lungs from infected CF patients [4]. Despite the inflam-
matory response and intensive antibiotic therapy, most
infections caused by P. aeruginosa persist for long time,
eventually leading to respiratory failure and lung trans-
plantation or death [2].
Especially during early infection, P. aeruginosa
expresses a wealth of virulence factors exhibiting strong
pro-inflammatory properties [5]. Among these, pro-
teases can disrupt lung tissue and modulate host
inflammatory response [6–8]; the blue-green pigment
pyocyanin causes host cells oxidative stress and dysre-
gulates immune mechanisms [9–11]; the siderophore
pyoverdine is both able to sequester iron from host
depots and to regulate bacterial virulence [12,13]. In a
previous study, we observed that macrolide antibiotic
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azithromycin (AZM) acts on P. aeruginosa by reducing
the synthesis of proteases and other exoproducts
involved in bacterial virulence and the associated host
inflammatory response. Indeed, AZM is known to
interact with the 50S ribosomal subunit and affect
specific genes and transcriptional factors involved in
the regulation of virulence [14]. This inhibitory action
was associated with a decrease of lung immune
response in mice with beneficial effects for the animals
in terms of reduced inflammation [15], suggesting that
bacterial virulence down-regulation might be a promis-
ing anti-inflammatory strategy.
Patients with chronic P. aeruginosa lung infection
are often treated with AZM because of its anti-pseu-
domonal and immunomodulatory properties [16,17].
Unfortunately, there is a number of patients that do
not benefit from AZM therapy or that show adverse
effects to the drug [18]. Especially for these patients,
it is important to find alternative treatments. In the
last 15 years, various studies were conducted to eval-
uate therapy with clarithromycin (CLM), another
macrolide antibiotic. Although the comparison of
the outcomes of these studies is limited by the dif-
ferent treatment regimens, doses, drug formulations
and clinical factors evaluated, low-dose CLM seems
to be more effective, as supported also by its low-
dose benefits in the treatment of diffuse panbronch-
iolitis which shares many similarities in clinical and
pathological characteristics with CF [19–23].
Moreover, CLM treatment was shown to decrease
lung inflammatory processes and chronic airways
hypersecretion in non-CF patients with bronchiecta-
sis [24,25]. Pertaining to its anti-pseudomonal effects,
CLM has no bactericidal activity against P. aerugi-
nosa, like other macrolides, but can interfere with
protein synthesis and inhibit protease expression,
twitching motility and biofilm maturation, promoting
biofilm permeability and favoring penetration of
other antimicrobial agents like ciprofloxacin and
tobramycin, also used in CF therapy [26–28].
Although the combination of anti-bacterial and
anti-inflammatory action in a single molecule might
seem particularly appealing, the use of antibiotics
also favors the selection of resistant bacteria, limiting
the long-term use of these molecules. Indeed, AZM
shows beneficial effects in the first year of therapy
while the reduced efﬁcacy associated with longer
treatment might be due to development of bacterial
resistance [29]. Therefore, in addition to the devel-
opment of new antibiotics, also alternative, non-anti-
biotic anti-inflammatory therapies, targeting the
damaging and pro-inflammatory effects of virulence
factors like proteases, might help to face this concern
[30]. The most potent anti-protease molecules are
hydroxamate-based broad spectrum matrix metallo-
protease inhibitors (MMPIs), which mimic collagen
structure, thus binding to the enzyme active site and
inactivating it by chelation of the catalytic zinc ion.
Interestingly, their inhibitory effect can apply also to
bacterial metalloproteases, as it has been demon-
strated by Ilomastat (Galardin, GM6001) ability to
inhibit thermolysin and P. aeruginosa elastase [31].
Ilomastat reached phase III clinical trials as therapy
for corneal ulcers and underwent pre-clinical devel-
opment as topical post-injury treatment for chemical
burns, as therapy for diabetic retinopathy and cancer
and as inhaled treatment for chronic obstructive pul-
monary disease [32–34]. The first MMPI to be clini-
cally tested was Batimastat, an injectable drug,
rapidly abandoned in favor of the newer, orally avail-
able analogue Marimastat which also entered clinical
trials as anticancer agent (glioblastoma, breast, ovar-
ian, pancreatic, gastric, small and non-small cell lung
cancers). Marimastat showed a favorable pharmaco-
kinetic profile, high systemic bioavailability, linear
dose-plasma relationship, balanced excretion (75%
hepatic, 25% renal), an elimination half-life compati-
ble with twice-daily dosing and modest efficacy in
delaying disease progression. However, significance
could not be established due to dose-limiting toxicity,
identified with appearance of musculoskeletal symp-
toms reversible upon drug discontinuation [35,36].
The intense clinical development of these molecules,
associated with the opportunity to target proteases
involved in chronic infection processes, suggest
their possible application to respiratory infectious
diseases like CF lung infection.
In this study, we investigated anti-virulence proper-
ties of CLM and MMPIs against P. aeruginosa and their
beneficial effects on lung inflammation in mice.
Results
Clarithromycin reduces secreted virulence factors
P. aeruginosa strains secrete various amounts of pro-
teases, pyocyanin and pyoverdine, as measured in their
culture supernatant. Particularly, VR1 strain, isolated
from a patient with intermittent infection, showed abil-
ity to secrete higher amounts of virulence factors in
comparison to laboratory strain PAO1 and other clin-
ical strains from both intermittently and chronically
infected patients (Suppl. Figure 1). Performing MIC
assay, we established that doses up to 256 µg/ml CLM
had no bacteriostatic activity against the selected strains
(Table 1). Thus, we measured proteases, pyocyanin and
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pyoverdine in culture supernatant of bacteria grown in
presence of a sub-MIC dose of CLM (45 µg/ml). As
shown in Figure 1, this treatment caused the reduction
of the levels of proteases in all protease-secreting
strains, while the inhibitory effect on pyoverdine and
pyocyanin varied among the tested strains. Particularly,
VR1 strain showed a significant reduction of all the
three virulence factors, similar to what we previously
observed with AZM [15]. Iron levels in culture medium
seem not to interfere with CLM effect on pyoverdine
(Suppl. Figure 2).
This inhibitory effect does not concern bacterial
growth; indeed, CLM did not affect growth rate and
cell viability of VR1, the strain most inhibited by the
macrolide in terms of virulence factors secretion
(Figure 2). Thus, probably by interfering with the pro-
duction of P. aeruginosa exoproducts as previously
shown by AZM inhibiting metalloproteases synthesis
Figure 1. Proteases (A), pyocyanin (B) and pyoverdine (C) measured in culture supernatant collected from P. aeruginosa strains
grown in absence/presence of 45 ug/ml CLM. Each value represents the mean ± SEM of 3 experiments. Statistical analysis was
performed by Mann-Whitney test; *p < 0.05, **p < 0.01, ***p < 0.001 and **** p < 0.0001.
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[15], CLM could reduce bacterial virulence and indir-
ectly modulate virulence-induced host inflammatory
response.
Culture supernatant lacking virulence factors does
not induce inflammation in mouse lungs
To evaluate in vivo the possible reduction of inflamma-
tion associated with inhibition of P. aeruginosa viru-
lence exoproducts, we used a transgenic mouse model
that was previously validated [15,37,38]. In presence of
lung inflammatory response induced by non-invasive
intratracheal challenge with culture supernatant, the
exogenous IL-8 promoter is recognized by the mouse
transcriptional apparatus and luciferase enzyme is pro-
duced. At 4, 24 and 48 hours after treatment, biolumi-
nescence emission in the chest region was recorded
following D-luciferin injection. As shown in Figure 3,
in both WT and CF animals the challenge with VR1
culture supernatant induced after 24 hours a strong
inflammatory response in terms of IL-8 reporter activa-
tion. The bioluminescence signal lasted longer in CF
mice, whose emission after 48 hours was still signifi-
cantly higher than in mice challenged with the control
medium. Interestingly, in both animal strains, the
supernatant collected from VR1 grown in presence of
45 µg/ml CLM (VR1+ CLM) and containing lower
levels of virulence factors provoked only a minor
response: the average of photons emitted was
Table 1. Description of P. aeruginosa strains and CLM antimi-
crobial activity.
Bacterial strain Origin Phenotype MIC (µg/ml)
PAO1 Laboratory strain Non Mucoid > 256
VR1 CF intermittent infection Non Mucoid > 256
VR2 CF intermittent infection Mucoid > 256
CFC20 CF chronic infection Non Mucoid > 256
CFC21 CF chronic infection Non Mucoid > 256
Figure 2. Growth curves (A), growth rate (B) and CFU count (C) measured from VR1 growth in absence/presence of 45 ug/ml CLM.
Absorbance at 600 nm was measured every hour for 6 hours (A) and growth rate per minute was calculated from exponential phase
of growth curves (B). CFU were counted on TSA after plating serial dilutions of inocula (C). Each value represents the mean ± SEM of
3 experiments.
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significantly lower than in mice challenged with VR1
supernatant and comparable to the bioluminescence
signal induced by the control medium.
Protease inhibition reduces inflammation in mouse
lungs
Focusing on a specific family of virulence factors, we
evaluated the ability of human MMPIs Ilomastat,
Batimastat and Marimastat to inhibit P. aeruginosa
proteases secreted in VR1 culture supernatant. As
shown in Figure 4, Ilomastat had the best inhibitory
effect, producing a strong inactivation of bacterial pro-
teases already at 50 µM and reaching 89% inhibition at
150 µM. At 150 µM, also Marimastat induced a 65%
inhibition of the protease activity, whereas Batimastat
had poor inhibitory effect on bacterial proteases even at
higher concentrations (up to 300 µM, data not shown).
To evaluate in vivo the possible reduction of
inflammation associated with inhibition of proteases,
we monitored the IL-8 reporter activation induced by
non-invasive intratracheal challenge with VR1 culture
supernatant pre-treated with Ilomastat and
Marimastat by in vivo imaging. As shown in
Figure 5, protease inhibition with 50 µM Ilomastat
could slightly reduce the bioluminescence signal only
in WT mice but was insufficient in CF mice.
Increasing the dose to 150 µM, a significantly dimin-
ished emission was observed in both mouse strains at
24 hours after the challenge. Regarding Marimastat,
the same concentration (150 µM) was even more
effective, since bioluminescence emission in CF
mice was still significantly reduced at 48 hours after
the intratracheal challenge with the pre-treated
supernatant.
Figure 3. Representative images (upper panels) and photon emission measurement (lower panels) of bioluminescence emission in
WT (A, C) and CF (B, D) mice challenged with concentrated culture supernatant from VR1 grown in absence/presence of 45 ug/ml
CLM. Control mice were treated with TSB. Photon emission is expressed as folds of increase (FOI) vs. baseline. Each value represents
the mean ± SEM of 6 animals (biological replicates) per group. Statistical analysis was performed by 2way ANOVA followed by
Dunnett’s multiple comparisons test; *p < 0.05, ***p < 0.001, **** p < 0.0001.
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Discussion
Patients with chronic P. aeruginosa lung infection are
often treated with low-dose AZM, a macrolide
antibiotic known to interact with the 50S ribosomal
subunit and affect specific genes and transcriptional
factors involved in the regulation of virulence [14].
AZM has no bactericidal activity against P. aeruginosa
but previously showed the ability to reduce secreted
virulence factors such as pyocyanin, pyoverdine and
proteases, due to its inhibitory effect on protein synth-
esis [15]. The observed anti-virulence activity is likely
to be involved in the clinical benefits associated with
AZM treatment in the first year of therapy while the
reduced efﬁcacy associated with longer treatment dura-
tion might be due to development of bacterial resis-
tance to AZM anti-virulence activity. Thereby,
evaluation of molecules with similar antibacterial
mechanisms is important to find alternative treatments
for patients not responding to AZM or for whom the
treatment lost efficacy during time [18,29].
Macrolide CLM already showed clinical effectiveness
in treating diffuse panbronchiolitis and has been stu-
died as therapy for other respiratory diseases [23–25];
CLM effects in CF patients were also evaluated in
different studies, although with contrasting outcomes
Figure 4. Protease activity in VR1 concentrated culture super-
natant was measured in presence of MMPIs Marimastat (MAM),
Batimastat (BAM) and Ilomastat (ILM). Each value represents the
mean ± SD of 3 experiments. Statistical analysis was performed
by Kruskal-Wallis test and Dunn’s multiple comparisons test; *
p < 0.05, **p < 0.01, ***p < 0.001, **** p < 0.0001 vs. non-
treated supernatant (0 µM MMPIs).
Figure 5. Representative images (upper panels) and photon emission measurement (lower panels) of bioluminescence emission in
WT (A, C) and CF (B, D) mice challenged with VR1 concentrated culture supernatant pre-treated with 50 and 150 µM Ilomastat (ILM)
and 150 µM Marimastat (MAM). VR1 supernatant was used as positive control (black), TSB was used as negative control. Photons
emission is expressed as folds of increase (FOI) vs. baseline. Each value represents the mean ± SEM of 6 animals (biological
replicates) per group. Statistical analysis was performed by 2way ANOVA followed by Dunnett’s multiple comparisons test; *p < 0.05,
**p < 0.01, ***p < 0.001, **** p < 0.0001.
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[19–22]. Like AZM, low-dose CLM has no bactericidal
activity against P. aeruginosa, but we observed that it
can lower the amount of virulence factors secreted by P.
aeruginosa and reduce the associated host inflamma-
tory response in both WT and CF mice. Although our
results seem in contrast with previous findings [39]
reporting higher mortality rate in mice infected with
macrolide-treated P. aeruginosa, the different challenge
must be considered. Our investigation is focused on
secreted exoproducts, while the infection process
involves other factors, like biofilm formation. Indeed,
CLM is known to inhibit maturation of established
biofilm but not its formation [26,40], which might
partially explain the observations from Kobayashi and
colleagues.
Our results support that CLM acts similarly to AZM,
thus it might represent a candidate therapy for treating
CF patients with chronic infection. We encourage more
clinical trials to assess the effectiveness of this therapy,
which gain particular interest when considering the
possibility of local aerosol administration; indeed, its
formulation as dry powder inhaler is currently under
investigation [28]. To our knowledge, CLM treatment
has never been tested in patients that already showed
no improvement under AZM therapy. A clinical study
in this group of patients might clarify the possible use
of CLM as an alternative therapy and help to under-
stand the involvement of P. aeruginosa resistance in
AZM long-term treatment ineffectiveness.
Among various virulence factors, proteases from
both host and bacteria play a critical role in CF lung
disease, contributing to lung tissue damage and exacer-
bation of the inflammatory response. P. aeruginosa
exogenous proteases such as AprA and LasB can alter
mucociliary clearance, degrade lung tissue and dysre-
gulate host immune system, thus strongly contributing
to lung disease [6]. We previously showed that P.
aeruginosa proteases are major exoproducts of selected
clinical strains and that they might interfere with the
host immune system by down-regulating CXCR1 on
the surface of human neutrophils [41].
Downregulation of protease production is part of the
anti-virulence effects of macrolides and is likely to be
involved in their anti-inflammatory effect associated
with virulence inhibition. Thus, molecules targeting
proteases might represent an alternative or comple-
mentary anti-inflammatory therapy in CF.
Among many classes of protease-inhibiting com-
pounds, broad spectrum hydroxamates are attractive
candidates, due to their intense clinical evaluation
during the 90’s when many members entered clinical
trials as cancer therapeutics [35,36]. Hydroxamate-
based broad spectrum MMPI Ilomastat had
previously been reported to inhibit P. aeruginosa
elastase [31]; indeed, we confirmed that Ilomastat
and its analogue Marimastat can reduce the protease
activity in P. aeruginosa culture supernatant and this
mechanism seems associated with anti-inflammatory
effects in mice. Although in vitro Ilomastat showed a
greater inhibitory effect on proteases in comparison
to Marimastat, in vivo Marimastat was more effective
in reducing lung inflammation. These discrepancies
might be due to MMPIs effects on the host side.
Indeed, MMPIs can inhibit also host proteases and
have been reported to interact with host inflamma-
tory response mechanisms like neutrophil and
macrophage recruitment [34,42]. Although we cannot
address a specific target, the possibility of an addi-
tional anti-inflammatory activity elicited by
Marimastat might represent a further advantage of
anti-protease therapy.
We cannot exclude that inhibition of host proteases
might also participate in the observed beneficial effects;
nevertheless, inhibition of host proteases like neutro-
phil elastase, thought to be the main source of protease
activity in CF lungs, might represent an additional
benefit of these molecules. These results highlight the
key role played by proteases in host inflammatory
response and suggest protease inhibition as an alterna-
tive strategy to dampen the inflammatory response and
concomitant airways damage. Particularly, inhaled
therapy with MMPIs [34] might avoid the side-effects
reported with oral Marimastat and potentially represent
a new local treatment for CF patients.
In conclusion, the results from our study highlight
the important role played by P. aeruginosa virulence
factors in CF host inflammatory response, support the
inhibition of these factors as a potential therapeutic
strategy and encourages the development of treatments
targeted against bacterial virulence.
Material and methods
Bacterial strains
P. aeruginosa laboratory strain PAO1 and clinical
strains VR1, VR2, CFC20, CFC21 [15,43] were used
in this study. Clinical isolates were previously col-
lected from sputum samples of patients followed at
the Cystic Fibrosis Center of Verona, Italy. VR1 and
VR2 strains were isolated from intermittently
infected patients; CFC20 and CFC21 strains were
isolated from chronically infected patients. VR2 is
characterized by mucoid morphology. Strains were
stored in MicrobankTM (Biolife Italiana, cat. n.
17PL170M) at −80°C.
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Minimum inhibitory concentration (MIC) assay
P. aeruginosa strains were streaked on tryptic soy agar
(TSA, Thermo Fisher Scientific, OxoidTM, cat. n.
CM0131R) plates and incubated at 37°C for
24–48 hours. 1–2 colonies were inoculated in 10 ml
tryptic soy broth (TSB, Thermo Fisher Scientific,
OxoidTM, cat. n. CM0129R) shaking at 37°C for
16 hours. Optical density (OD) at 600 nm was measured
using a spectrophotometer, cultures were diluted to 0.05
OD/ml and inoculated in 96-wells microtiter plates with
increasing concentrations of CLM (Klaricid, Abbott).
After incubation at 37°C for 16 hours, the MIC values
were identified as the lowest drug concentration causing
a complete inhibition of bacterial growth.
Growth curves
VR1 strain was plated on TSA plates and incubated at
37°C for 24–48 hours. 1–2 colonies were inoculated in
10 ml TSB shaking at 37°C overnight. OD600 was mea-
sured, culture was diluted to 0.05 OD/ml in 50 ml TSB
with/without sub-MIC CLM (45 µg/ml) and incubated
at 37°C shaking. OD600 was measured every hour and
growth rate was calculated using GraphPad Prism 7.0
software. After 6 hours, cultures were serially diluted
and plated on TSA. Plates were incubated at 37°C for
24 hours and colony forming units (CFU) were
counted.
Culture supernatant collection and concentration
P. aeruginosa strains were streaked on TSA plates and
incubated at 37°C for 24–48 hours. 1–2 colonies were
inoculated in 30 ml TSB shaking at 37°C for 16 hours.
OD600 was measured and cultures were diluted to 0.1
OD/ml in 30 ml of the same medium, with/without
sub-MIC CLM (45 µg/ml). After shaking at 37°C for
16 hours, cultures were diluted to 0.2 OD/ml and
centrifuged at 7000 g for 30 min at 4°C. Supernatants
were collected and sterile-filtered. For mice intratra-
cheal challenge, supernatants were 10X-concentrated
using 30 kDa cut-off Amicon Ultra-15 centrifugal filter
units (Merck Millipore, cat. n. UFC903024) pre-coated
with 10 mg/ml bovine serum albumin (Sigma-Aldrich,
cat. n. A2153). Concentrates were sterile-filtered and
stored at −20°C.
Azocasein assay
Protease activity in culture supernatants was determined by
azocasein assay. Briefly, 350 µl reaction mixture containing
0.1 M Tris-HCl pH 8.0 and 1% azocasein (Sigma-Aldrich,
cat. n. A2765) resuspended in 0.5% NaHCO3 was added to
150 µl supernatant with/without MMPIs Ilomastat,
Marimastat, Batimastat (Sigma-Aldrich, cat. n. M5939,
M2699, SML0041) and incubated at 37°C for 20 minutes
shaking. After addition of 1 ml 7% ice-cold perchloric acid,
the solution was centrifuged. 150 µl 10 N sodium hydro-
xide were added to the clear supernatant andODat 430 nm
was measured. One protease unit was calculated as the
amount of enzyme producing an increase of 1 OD unit
per hour.
Pyocyanin measurement
Pyocyanin was chloroform-extracted from culture super-
natants. Briefly, 3 ml chloroformwere added to 5ml super-
natant and the lower phase was mixed with 1 ml 0.2 M
hydrogen chloride. OD at 530 nm was measured in the
upper phase and pyocyanin concentration was calculated
by multiplying for its ɛ−1 (17,072 µg/ml cm) and normal-
izing for the optical distance.
Pyoverdine measurement
Pyoverdine was measured by OD at 405 nm in culture
supernatants and pyoverdine concentration was calcu-
lated using its ɛ (19 mM−1 cm−1) and normalizing for
the optical distance.
Experimental animals
Female congenic C57BL/6J wild-type (WT) and gut-cor-
rected CFTRtm1UNC (CF) mice (8–10 weeks old) were
purchased from Cystic Fibrosis animal Core facility (San
Raffaele Hospital, Milan, Italy). Animals were maintained
under conventional housing conditions. Prior to use, ani-
mals were acclimatized for at least 5–7 days to the local
vivarium conditions having free access to standard rodent
chow and tap water. Animal experiments were conducted
in compliance with national (Decreto Legislativo n. 26, 4
Marzo 2014) and international laws and policies (Guide for
the Care and Use of Laboratory Animals).
Reporter construct
Experimental animals were transfected with the bIL-8-
Luc construct, containing a luciferase gene under the
control of bovine IL-8 promoter (kindly provided by
Prof. Gaetano Donofrio, University of Parma, Italy)
[44]. Plasmid was transformed in competent E. coli
DH5α cells by heat shock and purified by Qiagen
Plasmid Maxi Kit (Qiagen, cat. n. 12,163) followed by
phenol:chloroform extraction with precipitation in iso-
propanol and 70% ethanol. Plasmid concentration and
purity were assessed using NanoDrop 2000c spectro-
photometer (Thermo Fisher Scientific).
In vivo gene delivery
In vivo JetPEI (Polyplus Transfection, cat. n. 201-50G) was
used as carrier for delivering bIL-8-Luc construct to lung
tissue. As previously described [37], DNA and JetPEI were
mixed with a final N/P ratio of 7–7.5 following
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manufacturer’s instructions. Briefly, 38–42 µg DNA and
5.3–6.3 µl JetPEI were separately diluted in 200 µl 5%
glucose, mixed, and incubated at room temperature for
15 minutes. 400 µl of the mixture were intravenously
injected through the tail vein after warming the animals
for 5 minutes under a heating lamp. Expression and inac-
tivation of the reporter were monitored by in vivo biolu-
minescence imaging after 24 hours and 7 days, respectively.
Intratracheal challenge
BIL-8-Luc transgenic mice were intratracheally chal-
lenged as previously described [37] with 10X-concen-
trated VR1 culture supernatant collected after growth
with/without sub-MIC CLM (45 µg/ml) or MMPIs-
treated/free. Briefly, mice were anesthetized with 2.5%
isoflurane and placed on an intubation platform hang-
ing by their incisor teeth. After visualization of the
opening of the trachea using a laryngoscope, 50 µl
stimulus were instilled by an intubation tube connected
to a pressure control system. After 4, 24 and 48 hours,
reporter activation was monitored by in vivo imaging.
In vivo bioluminescence imaging
Bioluminescence imaging of experimental animals was
performed as previously described [37], using IVIS
Spectrum imaging system (PerkinElmer). 10 minutes
prior to bioluminescence recording, mice were anesthe-
tized with 2.5% isoflurane and intraperitoneally
injected with 150 mg/kg D-Luciferin (PerkinElmer,
cat. n. 122,799). After 5 minutes-long luminescence
recording, photons emitted from chest region were
quantified using Living Image software (PerkinElmer).
Statistical analysis
Statistical analysis was performed using GraphPad Prism
7.0 software. Virulence factors measurements were ana-
lyzed by Mann-Whitney test, protease inhibition by
MMPIs was analyzed by Kruskal-Wallis test followed by
Dunn’s multiple comparisons test, and mice biolumines-
cence emission was analyzed by 2way ANOVA followed by
Dunnett’s multiple comparisons test.
Abbreviations
CF cystic fibrosis
AZM azithromycin
CLM clarithromycin
MMPI matrix metalloprotease inhibitor
TSA tryptic soy agar
TSB tryptic soy broth
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